354 related articles for article (PubMed ID: 33524942)
1. Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma.
Monie DD; Bhandarkar AR; Parney IF; Correia C; Sarkaria JN; Vile RG; Li H
Neurosurg Focus; 2021 Feb; 50(2):E10. PubMed ID: 33524942
[TBL] [Abstract][Full Text] [Related]
2. Intraarterial delivery of virotherapy for glioblastoma.
Srinivasan VM; Lang FF; Kan P
Neurosurg Focus; 2021 Feb; 50(2):E7. PubMed ID: 33524944
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Zika Virus: New Option for Glioblastoma Treatment.
Zhou C; Chen Q; Chen Y; Qin CF
DNA Cell Biol; 2023 Jun; 42(6):267-273. PubMed ID: 36350682
[TBL] [Abstract][Full Text] [Related]
4. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
[TBL] [Abstract][Full Text] [Related]
5. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell plasticity in glioblastoma multiforme: a perspective on future directions in oncolytic virotherapy.
Kim DS
Future Oncol; 2020 Oct; 16(28):2251-2264. PubMed ID: 32744059
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi YR; Schulze AJ
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
[TBL] [Abstract][Full Text] [Related]
8. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Blitz SE; Kappel AD; Gessler FA; Klinger NV; Arnaout O; Lu Y; Peruzzi PP; Smith TR; Chiocca EA; Friedman GK; Bernstock JD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163730
[TBL] [Abstract][Full Text] [Related]
10. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
12. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
13. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
14. Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas.
Monie DD; Correia C; Zhang C; Ung CY; Vile RG; Li H
Sci Rep; 2021 May; 11(1):11198. PubMed ID: 34045642
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy.
Wang S; Wei J
Int J Cancer; 2022 Nov; 151(10):1654-1662. PubMed ID: 35633046
[TBL] [Abstract][Full Text] [Related]
16. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma.
Cuoco JA; Rogers CM; Mittal S
Neurosurg Focus; 2021 Feb; 50(2):E8. PubMed ID: 33524945
[TBL] [Abstract][Full Text] [Related]
17. Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies.
Haddad AF; Young JS; Mummaneni NV; Kasahara N; Aghi MK
J Neurooncol; 2021 Mar; 152(1):1-13. PubMed ID: 33389564
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
19. Effects of oncolytic viruses and viral vectors on immunity in glioblastoma.
Liu P; Wang Y; Wang Y; Kong Z; Chen W; Li J; Chen W; Tong Y; Ma W; Wang Y
Gene Ther; 2022 Apr; 29(3-4):115-126. PubMed ID: 33191399
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option.
Asija S; Chatterjee A; Goda JS; Yadav S; Chekuri G; Purwar R
Front Immunol; 2023; 14():1118246. PubMed ID: 37006286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
